富马酸比索洛尔/精氨酸培哚普利(Bisoprolol fumarate/Perindopril arginine) - 药物靶点：ACE x β1-adrenergic receptor_在研适应症：冠状动脉疾病，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Bisoprolol/perindopril、Cosimprel、Cosyrel

+ [4]

靶点

ACE x β1-adrenergic receptor

作用方式

抑制剂、拮抗剂

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)、β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

心血管疾病

在研适应症

冠状动脉疾病高血压

非在研适应症-

原研机构

Les Laboratoires Servier SAS

在研机构

Les Laboratoires Servier SAS

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

比利时 (2015-10-12),

冠状动脉疾病高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C25H46N6O7

InChIKeyRYCSJJXKEWBUTI-YDYAIEMNSA-N

CAS号612548-45-5

查看全部结构式(2)

关联

3

项与富马酸比索洛尔/精氨酸培哚普利相关的临床试验

NCT04484688

/ Unknown statusN/A

Perindopril+Bisoprolol in Therapy of Patients With Atrial Fibrilation

The study aims to evaluate the effectiveness and safety of oral fixed-dose combination of bisoprolol/perindopril in patients with permanent atrial fibrillation

开始日期2020-08-01

申办/合作机构

Aversi Clinic

NCT04588935

/ Completed临床2期

To Develop and Implement a Method for Medical Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer

To develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular complications

开始日期2019-07-01

申办/合作机构

Republican Scientific & Practical Centre Cardiology

NCT03730116

/ CompletedN/A

Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE)

Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.
Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

开始日期2018-11-14

申办/合作机构

Servier Russia

100 项与富马酸比索洛尔/精氨酸培哚普利相关的临床结果

登录后查看更多信息

100 项与富马酸比索洛尔/精氨酸培哚普利相关的转化医学

登录后查看更多信息

100 项与富马酸比索洛尔/精氨酸培哚普利相关的专利（医药）

登录后查看更多信息

2

项与富马酸比索洛尔/精氨酸培哚普利相关的文献（医药）

2017-10-01·Vnitrni lekarstvi

COSYREL - an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure

Review

作者: Widimský, Jiří

Fixed combinations of two or three drugs are being frequently used in cardiovascular diseases. This approach markedly increases adherence of the patients to prolonged therapy and thus leads to better control of the diseases. Fixed combinations are often used in hypertension and coronary artery disease (CAD). Cosyrel is the first fixed combination of betablocker (bisoprolol fumarat) and ACE inhibitor (perindopril arginin) available in czech market. The advantage is availability in several concentrations (10 mg/10 mg, 10 mg/5 mg a 5 mg/10 mg a 5 mg/5 mg) , when first indicates bisoprolol dose and the second perindopril. This combination is indicated in arterial hypertension and/or in stable CAD (in patients after myocardial infarction or revascularisation) and/or in dosages 5 mg/5 mg and 5 mg/10 mg in patients with chronic heart failure with systolic dysfunction. This article aimed to evaluate briefly clinical characteristics of this fixed combination. Bisoprol and perindopril arginin have a lot of data indication their positive impact on CV risk and prognosis.Key words: bisoprolol - coronary artery disease - heart failure - hypertension - perindopril.

2017-05-01·Revue medicale de Liege

[Bipressil® : first single-pill combination of bisoprolol and perindopril arginine].

Review

作者: Canivet, A ; Gach, O ; Krzesinski, J-M ; Falque, B ; Lancellotti, P ; Krzesinski, F

In patients suffering from systemic arterial hypertension, coronary artery disease, or heart failure, beta-blockers and angiotensin-convertase enzyme inhibitors play a major therapeutic and preventive role. Coronary artery disease remains the leading cause of mortality in industrialized countries. Unless adapted preventive strategy, notably pharmacological interventions, cardiovascular events in these patients remain high. One reason for this relative failure is represented by non-adherence to treatment. A treatment consisting in an association in one pill of several different molecules should confer a higher treatment compliance and thus efficacy. This article describes the characteristics of the first available dual association between a cardioselective beta-blocker agent, bisoprolol, and an angiotensin-convertase enzyme inhibitor, perindopril arginine.

100 项与富马酸比索洛尔/精氨酸培哚普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C07FB07	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
冠状动脉疾病	比利时	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	保加利亚	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	克罗地亚	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	塞浦路斯	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	捷克	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	爱沙尼亚	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	法国	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	希腊	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	匈牙利	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	爱尔兰	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	意大利	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	拉脱维亚	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	立陶宛	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	卢森堡	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	波兰	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	葡萄牙	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	罗马尼亚	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	斯洛伐克	Les Laboratoires Servier SAS	2015-10-12
冠状动脉疾病	斯洛文尼亚	Les Laboratoires Servier SAS	2015-10-12
高血压	比利时	Les Laboratoires Servier SAS	2015-10-12